The estimated Net Worth of Dannielle Appelhans is at least $425 Тысяча dollars as of 8 December 2023. Ms Appelhans owns over 8,000 units of Rubius Therapeutics Inc stock worth over $611 and over the last 3 years she sold RUBY stock worth over $1,350. In addition, she makes $422,980 as Chief Operating Officer at Rubius Therapeutics Inc.
Ms has made over 5 trades of the Rubius Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently she bought 8,000 units of RUBY stock worth $14,320 on 8 December 2023.
The largest trade she's ever made was exercising 12,500 units of Rubius Therapeutics Inc stock on 9 August 2022 worth over $1,038. On average, Ms trades about 5,039 units every 49 days since 2021. As of 8 December 2023 she still owns at least 7,363 units of Rubius Therapeutics Inc stock.
You can see the complete history of Ms Appelhans stock trades at the bottom of the page.
Dannielle Appelhans is the Chief Operating Officer at Rubius Therapeutics Inc.
As the Chief Operating Officer of Rubius Therapeutics Inc, the total compensation of Ms Appelhans at Rubius Therapeutics Inc is $422,980. There are 7 executives at Rubius Therapeutics Inc getting paid more, with Pablo Cagnoni having the highest compensation of $1,721,130.
Ms Appelhans is 38, she's been the Chief Operating Officer of Rubius Therapeutics Inc since . There are 18 older and no younger executives at Rubius Therapeutics Inc. The oldest executive at Rubius Therapeutics Inc is Michael Rosenblatt, 69, who is the Independent Director.
Dannielle's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY ST, , CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over $2,165,279 worth of Rubius Therapeutics Inc stock and bought 305,000 units worth $6,624,680 . The most active insiders traders include Noubar Afeyan, Roger Pomerantz и Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $2,709. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth $1,350.
developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.
Rubius Therapeutics Inc executives and other stock owners filed with the SEC include: